BretonM, KovatchevB: One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther, 2021; 23:601-608.
2.
BattelinoT, DanneT, BergenstalRM, et al.: Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care, 2019; 42:1593–1603.
3.
PetrovskiG, Al KhalafF, CampbellJ, et al.: One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes. Acta Diabetol, 2021; 58:207–213.
4.
U.S. Food and Drug Administration FDA summary of safety and effectiveness data; PMA P160017. 2019. www.accessdata.fda.gov/cdrh_docs/pdf16/P160017B.pdf (accessed April 9, 2021).
5.
BeckRW, BergenstalRM, ChengP, et al.: The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diab Sci Tech, 2019; 13:614–626.
6.
VigerskyRA, McMahonC: The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther, 2019; 21:81–85.
